Palbociclib Capsule: A Bioequivalence Study in Healthy Subjects Under Fed Conditions to Compare Two Formulations

<b>Background:</b> Globally, breast cancer is the most frequently diagnosed neoplasm among women, with an estimated 2.3 million new cases reported in 2022. Treatment for hormone receptor-positive (HR+) advanced breast cancer includes aromatase inhibitors and CDK4/6 inhibitors such as palbociclib. <b...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Marcelo Gomes Davanço, Thaís Pereira Vespasiano, Jessé Moisan, Maira Eduarda Zanin, Gilberto Carlos Ruggiero Bernasconi, Marcia Aparecida Antonio, Oscar Gonzalez, Milesa Sarmiento, Mélanie Groleau
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2026-01-01
Serie:	Pharmaceutics
Soggetti:	palbociclib bioequivalence pharmacokinetics bioavailability generics advanced breast cancer
Accesso online:	https://www.mdpi.com/1999-4923/18/2/175
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!